NCT06416566View on ClinicalTrials.gov

Low-Dose Enoxaparin in Psoriasis

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

September 1, 2024

Study Completion Date

October 1, 2024

Conditions

Psoriasis

Interventions

DRUG

Subcutaneous Enoxaparin

Selected patients will receive subcutaneous low dose enoxaparin once a week for 6 weeks.The level of serum heparinase enzyme will be measured before and after treatment

All Listed Sponsors

lead

Zagazig University

OTHER_GOV

NCT06416566 - Low-Dose Enoxaparin in Psoriasis | Biotech Hunter | Biotech Hunter